SCHEDULE 13G/A: Wellington Management Group Discloses 11.9% Stake in Apogee Therapeutics

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting beneficial ownership of 11.9% of Apogee Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• Wellington Management Group LLP and its affiliates (Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP) collectively beneficially own 5,485,754 shares of Apogee Therapeutics, Inc. common stock.
• This aggregate beneficial ownership represents 11.9% of the class of securities.
• The filing is an Amendment No. 1 to a previous Schedule 13G, indicating an update to their prior disclosure.
• The shares are held in the ordinary course of business and were not acquired for the purpose of, or with the effect of, changing or influencing the control of the issuer.
• The reporting persons have shared voting power over 5,106,377 shares and shared dispositive power over 5,485,754 shares.
• Clients of Wellington's investment advisers are the record owners of these securities, and these clients have the right to receive dividends or proceeds from the sale of such securities.
• Vanguard Health Care Fund is identified as a client known to have the right or power with respect to more than five percent of this class of securities.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake by a reputable firm like Wellington Management Group is generally viewed positively as it signals confidence or strategic interest in the issuer. However, the document itself provides no operational or financial performance details of the issuer.

Positives

• A significant institutional investor, Wellington Management Group, holds a substantial stake (11.9%) in Apogee Therapeutics, which can be interpreted as a vote of confidence or strategic interest in the company.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist intent to influence control, which can provide stability.

Risks

• The document does not provide details on the specific investment thesis or future intentions of Wellington Management Group beyond passive ownership, which could lead to uncertainty regarding future stake adjustments.
• Changes in the ownership stake by a large institutional investor like Wellington Management Group could potentially impact the company's stock price.

Future Outlook

NA

Industry Context

This filing indicates continued or increased institutional interest in Apogee Therapeutics, Inc., a common occurrence for publicly traded companies, especially those in the biotechnology or pharmaceutical sectors where institutional investment is prevalent. The presence of a major asset manager like Wellington Management Group suggests the company is on the radar of significant institutional capital.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder can influence investor sentiment and potentially the stock price. It provides transparency regarding major ownership stakes, which is beneficial for market participants.

Key Dates

Keywords

Apogee Therapeutics, Wellington Management Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management